


Environmental Physiology at the Johnson Space Center: Past, Present, and Future


Johnny Conkin, Ph.D.

Universities Space Research Association

UTMB, Introduction to Aerospace Medicine
July 19, 2007







three guiding principles at JSC

- Keep healthy astronauts healthy.
 - a different approach than treating the sick
 - an occupational health model
- Risk reduction -- ALARA
 - we don't study decompression sickness (DCS), we limit the risk.
 - we don't study acute mountain sickness (AMS), we limit the risk.
 - we must stay non-invasive in what we do.
- Operational reality
 - Use what you know, very often forced to extrapolate.
 - JSC is not a medical or academic research center.


consequences of these principles

- We do more prevention than treatment.
- We often lack specific data for specific questions because we respond to immediate needs.
- A non-invasive approach maximizes subject safety but limits research opportunity.
- We constantly assess risk as:
 - the probability of the event and consequence of the event.

environmental physiology

- Pressure
 - hypobaric and hyperbaric
- Gases
 - hypoxia and hyperoxia
 - hypercapnia – closed space issues
 - inert gas physiology / respiration
- Temperature
 - hypothermia and hyperthermia
 - thermal comfort
 - Protective clothing
 - diving, aviation, mountaineering, space
- Acceleration
- Noise and Vibration
- Exercise / Performance
- Acclimatization / Adaptation
 - engineering solutions when necessary


we don't like rapid pressure change



environmental chambers at JSC

- Environmental Test Article
- 11-foot chamber
- 8-foot chamber
- Skylab simulation chamber
- Two hypo and two hyperbaric chambers
- Chamber B
- “giant” thermovacuum chamber
- Neutral Buoyancy Laboratory
- Space suit / personal rescue sphere
- Thermal chamber





In-suit Doppler Bubble Detector



reducing the risk of decompression sickness


Program	Cabin Pressure, (psia)	Cabin Oxygen Concentration volume %	EVA Suit Pressure, (psia)	EVA O ₂ Pre-breathe Time, minutes	EVA Prebreathe Conditions
Mercury	5	100	-	-	-
Gemini and Apollo	5	100	3.75	0	-
Skylab	5	70	3.75	0	-
Shuttle	10.2	26.5	4.3	40	In-suit (36 hrs at 10.2 psia)
	14.7	21	4.3	240	In-suit
ISS	14.7	21	4.3	120-140	Mask and in-suit; staged w/exercise
				240	In-suit

classification of DCS





- Type I – pain-only
 - “pain” as just an awareness (Grade 1)
 - “pain” at a threshold (Grade 2)
 - “pain” enough to impair performance, and therefore stop a test (Grade 3)
- Type II – serious DCS
 - should stop an EVA
 - could result in long-term injury, or even death
- Ultrasound monitoring for venous gas bubbles is a non-invasive way to understand decompression stress and monitoring for arterial gas is a safety plan.

Doppler Ultrasound Technology

- Non-invasive measure of decompression stress
- Spencer 0 – IV Venous Gas Emboli Scale
- Monitor
 - Pulmonary artery – all of cardiac output
 - Subclavian vein
 - Mid-cerebral artery – where it really matters
 - Four chamber view of the heart








**Tissues, especially adipose,
dump bubbles in venous system**

pulmonary artery VGE video



four-chamber ultrasound video





CHILLED WATER RETURN

AIR

6.7.2004 14:56



6. 7. 2004 14:54

Argo II, 1994



exercise

during

prebreathe


is

now



hot



1983 – 2007: 914 exposures, 121 cases of DCS with 7 classified as Type II



783 exposures, 326 with VGE detected



the probability of DCS

- simple probability models are:

$P(\text{DCS}) = \text{dose}^a / (\text{dose}^a + b^a)$ “Hill function”


$P(\text{DCS}) = 1 - e^{-\text{dose}}$ “survival function”

$P(\text{DCS}) = 1 / (1 + e^{(-B_0 - B_1 * \text{dose})})$ “logistic function”


- dose as simple one variable tissue ratio (TR)
- dose as more complex multivariable expression (TR, age, time, exercise, bubble volume, gender, etc.)

$$P_{1N_2} = P_0 + (P_a - P_0) * [1 - \exp(-\ln(2) / t_{1/2}) * \text{time}]$$

TR = P_{1N_2} / P_2 , where P_2 is 4.3 psia suit pressure



decompression sickness as dose-response






Fig. 1. The DCS and VGE failure distributions for data used in this analysis. Notice that each curve is "S" shaped, which helps to define an appropriate hazard function.

model
outcome




Fig. 3. The $P(\text{DCS})$ at either 3.5, 4.3, or 6.0 psia with (solid line) or without (dashed line) exercise at a particular time after decompression. The ratio of $P1N_2$ to $P2$ (TR) in Eq. 5 was 1.65 for each curve, but notice the $P(\text{DCS})$ increases as $P2$ decreases at any particular time after decompression. The 95% confidence interval is provided for the curve specific to the 4.3 psia exposure that included exercise.




Fig. 5. Predicted vs. observed DCS incidence in 66 groups used to fit Eq. 5. The area of a circle is proportional to the number of people in a group. The three dark circles are results from NASA tests at 4.3 psia with TRs between 1.60 and 1.65 where exercise is (2 circles above identity line) and is not (circle below identity line) part of the test (4). The model neither over or under estimates the entire data set, but did over estimate the incidence of DCS in several small groups that reported no symptoms.


goodness of fit




observations



the data we have







non-ambulating





ambulating







mild Type I DCS video




19 / 42 (45%) pain
got better




6 / 42 (14%) pain
got worse

17 / 42 (41%) pain
stayed constant



Type II, or “serious” DCS

- Seven Type II cases in 914 NASA exposures (1983 – 2007)
 - four of the seven had no O₂ prebreathe




examples of serious DCS


- substernal disturbance
- unproductive cough
- dyspnea
- disruptions of:
 - motor
 - sensory
 - cognitive pathways in brain and spinal cord
- paralysis
- ataxia
- dysmetria
- vertigo
- numbness
- aphasia
- amnesia
- altered mood

more examples


- tinnitus
- diplopia
- nystagmus
- hemianopsia
- confusion
- belligerence
- scatomo
- nausea
- cold sweat
- dyskinesia
- syncope
- severe headache
- vomiting
- pallor
- hallucinations
- depression



the puzzle of exercise and DCS











cutis marmorata –
several hours later!




treatment of DCS is a real challenge in space



back to the Moon, but in a different way



we want to stay longer and do more EVA



spacecraft atmosphere trade study

- Underlying Assumptions:
 - Efficient and frequent EVAs drive the exploration program.
 - Low pressure suit is always preferred to high pressure suit.
 - There is an operational value to a short in-suit prebreathe.
 - Vehicle atmosphere may not prevent risk of DCS during EVA.
 - Shuttle and ISS atmospheres are examples.
 - Dedicated hyperbaric treatment capability may not be present.
- Atmosphere Design Considerations:
 - Don't want a significant risk of fire – NASA has bad experience with 100% O₂.
 - Limit hypoxia – you need O₂ breath-by-breath.
 - Prevent DCS and VGE.
 - Better to prevent rather than treat DCS, or to constantly embolize the lung.
 - Optimize atmosphere to allow safe and efficient EVAs.


future spacecraft atmospheres

Environment	P_B		$F_{I}O_2$ (%)	$P_{I}O_2$ mmHg	$P_{A}O_2$ mmHg	Actual Altitude		Equivalent Air	
	psia	mmHg				m	feet	m	feet
<u>CEV + LSAM</u>									
normal	8.0	414	32.0	117	77	4,877	16,000	1,829	6,000
best case	8.2	424	34.0	128	86	4,816	15,800	1,158	3,800
worse case	7.8	403	30.0	107	68	5,029	16,500	2,438	8,000
<u>HABITAT</u>									
normal	7.6	393	32.0	111	71	5,182	17,000	2,286	7,500
best case	7.8	403	34.0	121	80	5,029	16,500	1,524	5,000
worse case	7.4	383	30.0	101	63	5,364	17,600	2,895	9,500

$P_{I}O_2$ is inspired O_2 partial pressure, computed as $(P_B \text{ mmHg} - 47) * F_{I}O_2$ (as decimal fraction).

$P_{A}O_2$ is computed acute alveolar oxygen partial pressure from alveolar oxygen equation.

Acute Mountain Sickness

- Signs and symptoms including headache, nausea, dizziness, fatigue, vomiting and sleeplessness following a recent gain in altitude with at least several hours at the new altitude in a hypoxic environment; likened to a bad hangover.
- 


incidence of AMS

- The incidence of AMS is highly variable.
 - Some may show mild AMS symptoms as low as 1,981-2,438m (6,500 - 8,000 ft).
 - One report claims that 25% of people are affected with quick ascent to 1,891m, with 90% of symptoms resolving in 3 – 4 days.
- Houston (1982) claims that 25-30% of people at 3,048m (10,000 ft) will experience some type of AMS.
 - This doubles at 4,200m (14,000 ft) and nearly all people will show some signs of AMS by 5,486m (18,000 ft).
- Roach (1998) says about 5% of people who develop AMS at 3,962m (13,000 ft) will go on to develop life threatening pulmonary and / or cerebral edema.

“typical” response to hypobaric hypoxic exposure

- Ascent causes a decrease in P_aO_2 sensed by the peripheral and central chemoreceptors, leading to increased rate of pulmonary ventilation (V_E) – **but some show little change in V_E .**
- Hyperventilation in response to hypoxia increases P_AO_2 and subsequently decreases P_ACO_2 and leads to a transient alkalosis.
- There is also a hypoxia-induced diuresis as the kidney attempts to establish normal pH with the excretion of bicarbonate – **but some show little change in urine output.**

acute hypobaric hypoxia video



the spectrum of hypoxia

- A sudden ascent to high altitude could kill you due to acute hypoxia while a gradual ascent to the same altitude could result in AMS or no symptoms at all.
- Symptoms of AMS take longer to develop (hrs-days).
- Severe and prolonged forms of AMS may lead to High Altitude Pulmonary Edema (HAPE) and High Altitude Cerebral Edema (HACE) and death.

Lake Louise AMS Scoring System

- Based on this committee's recommendations:
 - A diagnosis of AMS is based on a recent gain in altitude, at least several hours (>2) at the new altitude, and the presence of headache and at least one of the following symptoms: gastrointestinal upset, fatigue or weakness, dizziness or lightheadedness and difficulty sleeping.
- A score of three points or greater on the AMS Self-Report Questionnaire alone or in combination with the clinical assessment score is diagnostic of AMS.

Self Report Questionnaire

Each question asked and
the sum is calculated as
the AMS self report score.

1. Headache

- 0 No headache
- 1 Mild Headache
- 2 Moderate Headache
- 3 Severe Headache, incapacitating

2. Gastrointestinal
Symptoms

- 0 No gastrointestinal symptoms
- 1 Poor appetite or nausea
- 2 Moderate nausea or vomiting
- 3 Severe nausea & vomiting, incapacitating

3. Fatigue and/or
Weakness

- 0 Not tired or weak
- 1 Mild fatigue/weakness
- 2 Moderate fatigue/weakness
- 3 Severe fatigue / weakness, incapacitating

4. Dizziness /
lightheadedness

- 0 Not Dizzy
- 1 Mild dizziness
- 2 Moderate dizziness
- 3 Severe dizziness, incapacitating

5. Difficulty sleeping

- 0 Slept as well as usual
- 1 Did not sleep as well as usual
- 2 Woke many times, poor night's sleep
- 3 Could not sleep at all

Clinical Assessment

The interviewers ratings of three signs is added to the self-report score (Roach 1993)

6. Change in Mental Status

- 0 No Change in Mental Status
- 1 Lethargy / lassitude
- 2 Disoriented/confused
- 3 Stupor / semiconsciousness
- 4 Coma

7. Ataxia (heel to toe walking)


- 0 No Ataxia
- 1 Maneuvers to maintain balance
- 2 Steps off line
- 3 Falls down
- 4 Can't stand

8. Peripheral Edema

- 0 No peripheral edema
- 1 Peripheral edema at one location
- 2 Edema at two or more locations

This system helped to standardize the diagnosis of AMS.

a debate is underway


- Despite over a century of research there remains a vigorous debate on the etiology and pathophysiology of AMS.
 - Certainly the brain is the target organ of and responder to O₂ deprivation.
- 

Paul Bert (1833-1886)

- A French Physiologist considered the founder of Aerospace Medicine.
- Demonstrated, that the symptoms of AMS could be prevented or relieved by oxygen breathing and so **“Proved” that it was the decrease in partial pressure of oxygen & subsequent hypoxia at high altitude**, that caused AMS.
- This doctrine that low partial pressure of O_2 alone is the cause for AMS has held true for 150 years.



Loepkky, Roach, Tucker, et al

- But over the last thirty years, researchers have begun to question the conventional wisdom that the symptoms of AMS are solely due to low O_2 partial pressure.
- 

“the diminution of barometric pressure acts upon the living beings only by lowering the oxygen tension in the air, in the breath, and in the blood which supplies their tissues.... The increase in barometric pressure acts only by increasing oxygen tension in the air and blood....” Paul Bert, 1878.

- Consequently, maintaining sea level equivalent partial pressure of O₂ at any and all altitudes we “assume” no signs and symptoms of AMS should be seen.

Variable Pressure with Supposedly Equivalent Normoxia

<u>A</u>	<u>B</u>	<u>C</u>
21% O ₂ @ 760mmHg	31% O ₂ @ 523 mmHg	49% O ₂ @ 349mmHg
Sea Level	10,000 ft	20,000 ft
$P_{A}O_2 = 104$ mmHg	$P_{A}O_2 = 103$ mmHg	$P_{A}O_2 = 104$ mmHg

Equivalent normoxic air altitudes: $A = B = C$


no AMS is expected?

Variable Pressure with Supposedly Equivalent Hypoxia

<u>A</u>	<u>B</u>	<u>C</u>
14% O ₂ @ 760mmHg	21% O ₂ @ 523 mmHg	32.5% O ₂ @ 349mmHg
Sea Level	10,000 ft	20,000 ft
$P_{A}O_2 = 61$ mmHg	$P_{A}O_2 = 61$ mmHg	$P_{A}O_2 = 61$ mmHg

Equivalent hypoxic altitudes: $A = B = C$

all equal time-course and incidence of AMS symptoms?

- Accumulated anecdotal evidence shows descent is far more effective for relief of AMS than enriched O₂ breathing alone.
 - Essentially opening the doorway for further investigation of an independent pressure factor.
- 

Tucker, 1983

- Starts his experiments with subjects living at 1,524 m (5,000 feet).
- Takes them to 15,000 feet on air and site pressure on 14% O₂.


	Normoxic, P _A O ₂ = 103 mmHg	Hypoxic, P _A O ₂ < 103 mmHg
Normobaric, P _B = 760 mmHg	Altitude 1520 P _A O ₂ = 77 No AMS symptoms	Altitude 1520 m P _A O ₂ = 47.1 Mean AMS Score: 3.2
Hypobaric P _B < 760 mmHg		Altitude 4570 m P _B = 430 mmHg P _A O ₂ = 45 Mean AMS Score: 6.7



Roach and Loeppky, 1996

- Confirm the effect of hypobaria on the pathophysiology of AMS – hypobaric hypoxia caused modest hypoventilation combined with mild edema relative to normobaric hypoxia.

	Normoxic, $P_{A}O_2 = 103$ mmHg	Hypoxic, $P_{A}O_2 < 103$ mmHg
Normobaric, $P_B = 760$ mmHg	Altitude 1520 m $P_{A}O_2 = 76$ No AMS symptoms	Altitude 1520 m $P_{A}O_2 = 47.1$ Mean AMS Score: 2.0
Hypobaric $P_B < 760$ mmHg	Altitude 4570 m $P_{A}O_2 = 74.5$ Mean AMS score: 0.4	Altitude 4570 m $P_{A}O_2 = 46$ Mean AMS Score: 3.7



Lake Louise scoring system

the pressure effect!


- The pressure effect seems real, so to understand the total hypoxic stress means you have to understand the interaction between O_2 partial pressure and ambient pressure.
- A variety of explanations have been proposed for AMS and the effect of barometric pressure.



hypobaric hypoxia vrs normobaric hypoxia

- Decreased gas density relative to 1 ATA
 - Decreased quantity of gas in solution relative to 1 ATA
 - Increased insensible water loss relative to 1 ATA
 - Transient N₂ gradient out of tissues and CNS
 - Potential for VGE
- Gas density at 1 ATA
 - Gas in solution at 1 ATA
 - Insensible water loss at 1 ATA
 - Transient N₂ gradient into tissues and CNS
 - No potential for VGE

in the past....

- NASA's past habitats and vehicles did not expose the astronaut to a significant hypoxic condition.
 - Our only experience is with the shuttle staged denitrogenation protocol where astronauts are at the physiological equivalent of 4,000 feet altitude.
 - Likelihood of AMS almost nil.
- 



Vision for Space Exploration (2004)

- Specifies the development of human missions to the Moon, and then Mars.
- In order to accomplish this task NASA is required to build new interplanetary spacecraft, landers, space suits, rovers and surface habitats.






- The atmospheres for these spacecraft, landers, surface habitats, and rovers will likely be hypobaric, and a little hypoxic.
- Future Moon and Mars missions with CEV, LSAM and lunar habitat will require efficient EVA egress with minimal prebreathe time while still avoiding DCS and VGE.
- The combination of hypobaria and hypoxia simulates the conditions encountered by mountain climbers.



SO.....

Are we putting future astronauts at an increased risk for AMS ??????

Assume that we are, and develop a plan to mitigate the risk --- the JSC philosophy.



what happens if astronauts develop AMS?

- Based on extrapolation of current research it seems unlikely that anyone will experience severe AMS.
- The bigger issue is likely “performance”, we want to maximize performance.
- The bigger issue is a mitigation plan.




performance

- We are dealing with performance issues and mission success, not life and death, with the AMS anticipated in the CEV.
- We want to maximize performance and minimize any medical issues that impact mission success.
- Montgomery (1989) stated that the incidence of AMS at 1,981m (6,500 ft) was approximately 12% and further stated that **50% of these subjects took medication for relief of symptoms.**

prevention and treatment of AMS

- Preadaptation
- Preselection
 - The best predictor of AMS is history of prior episodes.
- Mild AMS is treated by:
 - Halting or slowing ascent
 - Acclimatization
 - Acetazolamide (125-250 mg BID)
 - O₂ therapy via mask or canula

other considerations

- Potential negative synergy between mild hypoxia and adaptation to μG .
 - Does μG change the incidence of AMS?
 - redistribution of lung fluid
 - increased interstitial edema
 - altered incidence of HAPE?
- 

optimum HCT for O₂ transport

Relationship between haematocrit and blood viscosity





Fig. 5-5.—A, relative viscosity vs hematocrit for human blood and camel blood. B, the transport of oxygen through a glass tube vs hematocrit, with a constant driving pressure.

anticipated work in environmental physiology

- NASA / JSC has worked with:
 - USAF
 - Brooks AFB
 - White-Patterson AFB in the distant future
 - Canadian Space Agency
 - DR&D – Toronto
 - Japanese Space Agency
 - Universities / Medical Centers
 - Duke University
 - University of Texas
 - University of Pennsylvania
 - Mayo – looking to the future

potential work to do in DCS

- Quantify PFO as a risk factor toward serious DCS.
- Understand the role of micronuclei in the genesis of bubbles.
- Consequence of air break in prebreathe – in progress.
- Exercise and accelerated N₂ washout.
- Exercise and change in micronuclei distribution.
- Validation of the current denitrogenation procedure for lunar EVAs.
- Data Mining -- Biophysical / statistical modeling of DCS.
- Effective DCS treatment at remote sites.
- Gender and risk of DCS and VGE.
- Application of ultrasound technology to monitor and understand decompression stress.
- Use of argon as an inert gas available on Mars.

potential work to do in AMS

- Quantify the risk and impact of AMS for modest hypoxic exposures.
- Specific experiments about AMS based on the atmospheres and conditions for the proposed CEV, LSAM, and surface habitats.
- Determine who may be at risk for developing AMS.
- Understanding the physics and physiology of the ambient pressure effect on AMS.
- Validate risk mitigation plans for AMS.





thank you from the
folks at JSC
johnny.conkin-1@nasa.gov